Bank Of Montreal Xencor Inc Transaction History

Bank Of Montreal

$233 Billion
Q3 2025

A detailed history of Bank Of Montreal transactions in Xencor Inc stock. As of the latest transaction made, Bank Of Montreal holds 21,858 shares of XNCR stock, worth $326,339. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,858

Previous 28,209 22.51%

Holding current value

$326,339

Previous $221,000 15.84%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$7.0 - $11.73 $44,457 - $74,497	-6,351 Reduced 22.51%	21,858 $256,000
Q2 2025 Aug 05, 2025	BUY	$7.52 - $11.26 $130,705 - $195,710	17,381 Added 160.52%	28,209 $221,000
Q1 2025 May 13, 2025	BUY	$10.64 - $24.13 $4,468 - $10,134	420 Added 4.04%	10,828 $115,000
Q4 2024 Feb 13, 2025	BUY	$19.43 - $26.84 $202,227 - $279,350	10,408 New	10,408 $239,000
Q2 2024 Aug 14, 2024	BUY	$18.21 - $24.5 $161,759 - $217,633	8,883 New	8,883 $168,000

Q2 2023 Aug 02, 2023	BUY	$24.77 - $29.9 $7,530 - $9,089	304 Added 4.1%	7,713 $192,000
Q1 2023 Jun 13, 2024	BUY	$25.95 - $36.95 $238,843 - $340,087	9,204 New	9,204 $256,000
Q4 2022 Feb 01, 2023	BUY	$24.79 - $30.86 $183,669 - $228,641	7,409 New	7,409 $192,000
Q2 2022 Aug 11, 2022	SELL	$19.74 - $29.01 $349,220 - $513,215	-17,691 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$26.68 - $41.63 $9,871 - $15,403	-370 Reduced 2.05%	17,691 $488,000
Q4 2021 Feb 11, 2022	SELL	$33.67 - $43.44 $1.09 Million - $1.41 Million	-32,450 Reduced 64.24%	18,061 $737,000
Q3 2021 Nov 12, 2021	BUY	$30.65 - $35.68 $8,612 - $10,026	281 Added 0.56%	50,511 $1.72 Million
Q2 2021 Aug 12, 2021	BUY	$34.33 - $44.68 $1.72 Million - $2.24 Million	50,230 New	50,230 $1.77 Million

Others Institutions Holding XNCR

# of Institutions

216

Shares Held

81.9M

Call Options Held

Put Options Held

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $891M
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account